Navigation Links
Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
Date:2/26/2008

NAPA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that results of a clinical study of Pyratine-6(TM) have been featured in the February issue of the Journal of Drugs in Dermatology.

The study was implemented to determine the efficacy and tolerance of topical Pyratine-6(TM) over 12 weeks for improving the baseline clinical signs and symptoms of photodamaged facial skin. In the single-arm longitudinal study with observations at 2, 4, 8, and 12 weeks, efficacy and safety were evaluated by clinical observations, digital photography, transepidermal water loss (TEWL), skin capacitance, and silicon replicas at each time point.

The study concluded that treatment with Pyratine-6(TM) over 12 weeks improves roughness and skin moisturization in 2 weeks compared to baseline and mottled hyperpigmentation (brown spots and discoloration) and fine wrinkles in 4 weeks compared to baseline. Reduction in facial erythema was observed as early as two weeks.

Dr. Jerry McCullough, lead investigator in the study stated, "In addition to the encouraging results in the treatment of photodamaged skin overall, another important finding is the significant reduction in erythema at 2 weeks and the additional reductions at weeks 4, 8, and 12. To my knowledge, this is the first report to show reduced erythema associated with use of a topical non-prescription therapeutic product."

"We are delighted to have made this important treatment available through leading plastic surgeons and dermatologists across the country", said Frank Massino, Chairman and Chief Executive Officer of Senetek, "and look forward to extending the significant clinical findings for Pyratine-6(TM) through additional ongoing clinical investigation."

About Dr. McCullough:

Dr. Jerry McCullough is a pioneer in the field of Dermatopharmacology. During his academic career he has effectively combined his expertise in pharmacology to the basic and clinical areas of dermatology. His work in dermatopharmacology has focused on the skin barrier properties and topical delivery of drugs. He has worked extensively with pharmaceutical companies in the development of effective topical drug delivery systems and has written over 40 IND applications for testing new topical therapies for skin disorders. His work is unique, in that drug development is taken from formulation testing in vitro to studies in experimental models, and finally to clinical testing in patients.

Dr. McCullough joined the faculty of the Department of Dermatology of the University of California, Irvine School of Medicine in 1979, where he is currently a Professor of Dermatology and Director of the Dermatology Clinical Research Center. Dr. McCullough earned his Bachelor of Science degree in chemistry from Indiana University and his Ph.D. in pharmacology from Yale University.

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
2. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
3. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
4. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
5. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
6. Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans
7. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
8. Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
9. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
10. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
11. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):